https://www.selleckchem.com/pr....oducts/srt2104-gsk22
d COVID-19 are needed to better assess the clinical outcomes in these patients. This report provides an overview of the characteristics, treatment, and outcomes of MG in COVID-19 patients. Although COVID-19 may exaggerate the neurological symptoms and worsens the outcome in MG patients, we did not find enough evidence to support this notion. Further studies with larger numbers of patients with MG and COVID-19 are needed to better assess the clinical outcomes in these patients.Individuals at clinical high-risk for psychosis (C
Like
Comment
Share
